Disease survival and progression in TARDBP ALS patients from Sardinia, Italy

ConclusionsTARDBP patients have a better survival/prognosis than C9orf72-positive and nmALS patients. King ’s staging also suggested that the higher survival rate and the slower progression associated with the TARDBP mutation could mainly be attributed to the longer time elapsed between King’s stages 2B to 3.
Source: Journal of Neurology - Category: Neurology Source Type: research